SNSriram S. Narsipur

Sriram S. Narsipur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sriram S. Narsipur has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Case-Based Framework for Teaching Artificial Intelligence Applications in Medical Education

    by Rafael C. Schulman, Ali Shervin Razavi, Céline Hardy, Prithi Chakrapani, Abdel Rhman Daoud, Mitchell Mazza, Ankita Saxena, Jason Grullon, Philip J. Gary, Frank Middleton, et al.

  • Open Access

    Chronic Kidney Disease in Ecuador: An Epidemiological and Health System Analysis of an Emerging Public Health Crisis

    by Irene Torres, Rachel Sippy, Kevin Louis Bardosh, Ramya Bhargava, Martín Lotto-Batista, Abigail E. Bideaux, Ramon Garcia-Trabanino, Amelia Goldsmith, Sriram S. Narsipur, Anna M. Stewart-Ibarra

    Background The absence of a chronic kidney disease (CKD) registry in Ecuador makes it difficult to assess the burden of disease, but there is an anticipated increase in the incidence of end-stage kidney disease along with increasing diabetes, hypertension and population age. From 2008, augmented funding for renal replacement treatment expanded dialysis clinics and patient coverage. Methods We conducted 73 in-depth interviews with healthcare providers in eight provinces. Findings were analyzed using qualitative methods and triangulated with quantitative data on patients with CKD diagnoses from six national-level databases between 2015 and 2018. We also reviewed grey and scientific literature on CKD and health systems in Ecuador. Results Datasets show a total of 17 484 dialysis patients in 2018, or 567 patients per million population (pmp), with an annual cost exceeding 11% of Ecuador’s public health budget. Each year, there were 139—162 pmp new dialysis patients, while doctors report waiting lists. The number of patients on peritoneal dialysis was stable; those on hemodialysis increased over time. Only 13 of 24 provinces have dialysis services, and nephrologists are in major cities, which limits access, delays medical attention, and adds a travel burden on patients. Prevention and screening programs are scarce, while hospitalization is an important reality of CKD patients. Conclusion CKD is an emerging public health crisis that has increased dramatically over the last decade in Ecuador and is expected to continue, making coverage for all patients impossible and the current structure, unsustainable. A patient registry would permit to estimate the demand and progression of patients with consideration for comorbidities, requirements and costs, and mortality, and identify where to focus prevention efforts. Health policy should clearly state CKD definitions and required patient data, including cause, disease stage and follow-up statistics. Organized monitoring of patients would benefit from improvements in patient referral.


  • Open Access

    Posterior Reversible Encephalopathy Syndrome After Renal Transplant: A Simple Solution for a Complicated Patient

    by David Haughey, Sriram S. Narsipur

    Background: Posterior reversible leukoencephalopathy syndrome (PRES) is characterized by an acute neurologic dysfunction coupled with characteristic findings on brain imaging. PRES occurs in the setting of hypertensive emergencies, eclampsia and as a neurotoxic effect of immunosuppressive agents. While overwhelmingly reversible without residual deficits when promptly recognized, vague symptomatology may delay the diagnosis of PRES. Results/Summary: A 50-year-old man who had undergone a recent kidney transplant was admitted to our clinic due to multiple episodes of seizure. He had no prior history of seizures or alcoholism. His transplantation had been without complication; he was discharged and given prednisone, tacrolimus, mycophenolate, acyclovir, trimethoprim-sulfamethoxazole, atenolol and enalapril. On the day of presentation, he experienced a severe headache, blurred vision and tonic-clonic seizure-like activity. His neurologic examination was limited by sedation, although no focal deficits were evident. Laboratory studies were unremarkable. A lumbar puncture revealed normal opening pressure, negative Gram stain, benign CSF analysis and India ink preparation. An MRI of the brain revealed bilateral enhancing parietal-occipital lesions, seen prominently on FLAIR sequence. Tacrolimus and all other medications were continued. The patient remained afebrile and normotensive and was extubated on the second hospital day. The patient reported no neurologic symptoms and was discharged on the third hospital day after a full recovery. Conclusions: While the outcome of PRES is typically benign, a delay in diagnosis may lead to permanent neurologic deficits, and misdiagnosis can be lethal. The cornerstone of treatment is removal of the offending agent or treatment of the underlying etiology. A clinical picture of headache, visual abnormalities, altered mentation and seizures is sufficient to prompt an empiric discontinuation of agents known to cause PRES. Calcineurin inhibitors such as tacrolimus are known to cause PRES, and in our patient, discontinuation led to a complete clinical resolution.


  • Open Access

    Cyclosporine: A Commentary on Brand versus Generic Formulation Exchange

    by A. K. Singh, S. S. Narsipur

    The evidence for conversion from brand name to generic equivalent cyclosporine is conflicting. Cyclosporine is a narrow therapeutic-range drug for which small variations in exposure may have severe clinical consequences for transplant patients. There is currently a lack of comparative outcome data relating to the pharmacokinetics of the reference formulation, Neoral, and generic formulations in transplant recipients. A major common concern is the potential inability to attain similar trough levels, an issue that can be easily corrected by ongoing therapeutic drug monitoring to ensure that the new steady state falls within an intended target range. Prospective clinical studies investigating the efficacy and safety of generic formulations in bothde novoand long-term transplant patients are also awaited. Until further evidence is available on the conversion of transplant patients to or between generic formulations of cyclosporine, any transfer to a different cyclosporine formulation should be undertaken with close supervision. The best available information to date, however, does not support the frequently held but unsubstantiated belief that generic preparations of immunosuppressive drugs are not as effective as brand names or that conversion from brand to generic is associated with significant danger. This paper attempts to initiate a discussion of these issues.


  • Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis

    by Philip T Ondocin, Sriram S Narsipur

    SUMMARY: Background:  Cardiovascular disease mortality among patients with end stage renal disease (ESRD) exceeds that which is predicted by traditional risk factors. Sudden death accounts for up to 15–38% of patients with ESRD found dead at home. Heart rate variability (HRV) is a reliable measure of autonomic modulation and has a very strong predictive value for ventricular arrhythmias and sudden death. A lower HRV is associated with increased risk. Modifying autonomic tone pharmacologically reduces death from dysrhythmia in the general population but has not been studied in ESRD.Methods:  We examined the effect of ramipril, an angiotensin converting enzyme inhibitor (ACEI) known in the general population to increase HRV, on cardiac function and heart rate variability in patients with renal failure. Eligible subjects on haemodialysis underwent a 2‐week washout period free of ACEI or beta blockers, during which time hypertension was treated with amlodipine, which has been shown not to affect HRV. Haemodynamic and HRV measurements were obtained at baseline and after subjects were treated for 4 weeks with an ACEI.Results:  Haemodynamics did not differ at 0 and 4 weeks. Baseline HRV values were markedly below those found in the general population, indicating pronounced predominance of sympathetic tone over vagal tone. Actual worsening of HRV with ACEI treatment was evident in several major time domains. The time domain SDNN (the standard deviation of all normal RR intervals) fell from 42.0 ± 24.8 ms to 20.1 ± 16.1 ms (P = 0.004) and the triangulation index fell from 178.0 ± 94.0 to 115 ± 59.2 (P = 0.01). A trend toward reduced HRV was seen in several other time domains.Conclusion:  These findings suggest that, unlike the general population, treatment of ESRD patients with an angiotensin converting enzyme inhibitor may cause a deleterious shift toward increased cardiac sympathetic nervous system tone.


  • Measurement of fiber bundle volume in reprocessed dialyzers

    by S.S. Narsipur

    Fiber bundle volume (FBV) is an important determinant of dialyzer re-use efficiency. This measurement is performed after the dialyzer has been pressure cleaned and may underestimate the degree of clotted fibers a patient actually encounters while on dialysis. Real-time online measure of FBV has been validated using an ultrasound dilution method and the Transonic HD01 monitor (Ithaca, NY, USA). Thirty-one stable chronic hemodialysis patients were studied during the first hour and then during the last 30 minutes of a typical dialysis session. Ultrasound velocity curves using a saline bolus were recorded by flow dilution sensors placed directly on the blood tubing using methods described previously. Blood volume within the dialyzer compartment was determined using a mathematical extrapolation of the measured transit time for a bolus of saline to pass through the dialyzer. These data were compared to FBV obtained using a Seartronics DRS4 (Fresinius, Walnut Creek, CA, USA) reprocessing machine both before and after the same dialysis session. At onset of treatment mean FBV by ultrasound was 100.0 +/- 2.7 ml and was unchanged at the end of the session at 100.0 +/- 3.1 ml (p = 0.49). Before a dialysis session, mean FBV measured on the DRS4 reprocessing machine was 123.5 +/- 2.1 ml and was unchanged following cleaning after dialysis at 121.7 +/- 2.0 ml (p = 0.20). The correlation coefficient between methods was 0.78. FBV did not change during a dialysis session using an online real-time measure. The results of this study do not support concerns that hemodialysis patients may experience considerably less efficient dialysis than standard FBV determination would suggest due to undetected clotting.


  • Mechanisms of Glomerular Immune Injury

    by Sriram S. Narsipur, Orjan W. Peterson, Robert Smith, Timothy D. Bigby, Sampath Parthasarathy, Francis B. Gabbai, Curtis B. Wilson, Roland C. Blantz

    Significant glomerular vasoconstriction and production of reactive oxygen species has been known to occur with exposure to anti–glomerular basement membrane antibody (AGBM-Ab) in the rat model. Previously published studies have demonstrated that such effects can be reduced by therapy with phentolamine, an α-adrenergic antagonist. It was hypothesized that antioxidant pretreatment with water-soluble probucol would improve glomerular hemodynamics 60 to 90 min after the administration of AGBM-Ab. These relationships were examined with both in vivo renal micropuncture and in vitro studies in rats. Single-nephron GFR (SNGFR) decreased markedly in untreated rats after AGBM-Ab as a result of afferent and efferent arteriolar vasoconstriction with consequent reductions in nephron plasma flow (SNPF) and decreases in the glomerular ultrafiltration coefficient (LpA). Basal SNGFR was increased, and SNGFR was significantly higher after AGBM-Ab in probucol-treated versus untreated rats. This finding was due solely to higher values for SNPF and prevention of afferent arteriolar constriction. A reduction in LpA after AGBM-Ab was not prevented by probucol treatment. In vitro analyses of glomeruli revealed reduced myeloperoxidase activity in antioxidant-treated rats. Lipoxygenase activity and leukotriene products, however, were not changed by antioxidant therapy, yet vasoconstriction was prevented. H2O2 generation before and after formyl-methionyl-leucyl-phenylalanine stimulation was significantly reduced before and after AGBM-Ab in glomeruli harvested from rats that were treated with the antioxidant. Antioxidant therapy in this model of AGBM-Ab injury did not prevent reductions in LpA, an index of glomerular membrane damage, but did prevent afferent arteriolar vasoconstriction. Reactive oxygen species generation was reduced by probucol. The specific mechanisms whereby antioxidant therapy ameliorates glomerular hemodynamic effects will be defined in additional studies and is likely to involve either enhanced vasodilator or diminished vasoconstrictor activity. E-mail narsipur@upstate.edu


    • 24 December 2002
      • Vol. 15  (6) , 713-5

    IgA nephropathy in a patient with chronic granulomatous disease.

    by Sriram S Narsipur, Paul F Shanley

    We report the first documented case of X-linked chronic granulomatous disease (CGD) in association with IgA nephropathy in a 22 year old male with multiple soft tissue abscesses. The case highlights the potential role of staphylococcal infections in the pathogenesis of IgA nephropathy and suggests the hypothesis that the neutrophil defect in CGD predisposes to such infections which may trigger IgA immune complex formation.